07:00 , Sep 5, 2016 |  BC Week In Review  |  Clinical News

Perhexiline: Phase IIb started

Heart Metabolics began an open-label, U.S. Phase IIb trial to evaluate once-daily oral perhexiline in about 33 patients with moderate to severe heart failure and preserved left ventricular function. Patients will receive a starting dose...
07:00 , May 5, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carnitine palmitoyl transferase 1 (CPT1)

Endocrine/metabolic disease INDICATION: Cachexia Cell culture and mouse studies suggest inhibiting CPT1 could help treat cachexia in cancer patients. In a xenograft mouse model of kidney cancer-associated cachexia and a mouse model of lung cancer-associated...
08:00 , Mar 10, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Carnitine palmitoyl transferase 1 (CPT1); CPT2; v-myc myelocytomatosis viral oncogene homolog (MYC; c-Myc)

Cancer INDICATION: Breast cancer Patient sample, mouse and cell studies suggest inhibiting CPT1 or CPT2 could help treat MYC-driven triple-negative breast cancer (TNBC). In TNBC patients, low tumor levels of acetyl-coenzyme A carboxylase β (...
07:00 , Apr 28, 2014 |  BioCentury  |  Finance

Targeted generic

Targeted generic Investors in Heart Metabolics Ltd. 's $20 million series A round think the company can use genetic testing to avoid the toxicities that have dogged perhexiline, a generic it is repurposing for hypertrophic...
00:53 , Apr 18, 2014 |  BC Extra  |  Financial News

Heart Metabolics secures $20 million in series A

Heart Metabolics Ltd. (Dublin, Ireland) raised an undisclosed amount in the first tranche of a planned $20 million series A round from venBio; Seroba Kernal Life Sciences; Brandon Capital Partners; and AshHill. Heart Metabolics is...
02:18 , Jan 3, 2013 |  BC Extra  |  Financial News

Heart Metabolics closes series A tranche

Heart Metabolics Ltd. (London, U.K.) raised $4 million in the first tranche of a planned $6 million series A round. Trans Tasman Commercialization Fund led the tranche, with participation from AshHill Investments. Additionally, Heart Metabolics...